Jingneng Biotechnology

Jingneng Biotechnology (Shanghai) Co., Ltd. (abbreviated as: Jingneng Biotechnology), established in February 2010, is a wholly-owned subsidiary of Boai Xinkaiyuan Pharmaceutical Co., Ltd. (stock code: 300109). It is a high-tech enterprise dedicated to the research, development, and application of medical, health, and technology services. Jingneng Biotechnology focuses on health and medical products as well as life science technology services, seizing the huge opportunities in China's health and medical industry and the rapid growth momentum of the life science market, forming an industrialized service system with product R&D and technology services at its core, covering fields such as life sciences, clinical diseases, and human health, and becoming a well-known Chinese high-tech enterprise with competitive advantages in product development, talent cultivation, marketing, sales channels, and professional services. Jingneng Biotechnology places emphasis on product development, establishing an innovative health and medical research center. With a senior expert team, internationally advanced instruments and equipment, and a comprehensive management and R&D system, the center has become a passionate, powerful, and promising research institution. Jingneng Biotechnology has passed the ISO9001:2008 quality system certification, and has taken the lead in becoming an official certified service provider for Illumina CSPro and BioNano, as well as a certified service provider for Roche NimbleGen targeted capture. Key technology platforms include the BioNano single-molecule optical map platform, Illumina-HiSeq high-throughput sequencing platform, Illumina-MiSeq personal genome analysis platform, Illumina-iScan gene chip platform, Roche LC480II real-time fluorescence quantitative PCR platform, Sequenom mass spectrometry analysis platform, Dawning high-performance server platform, and various supporting equipment. To date, articles published by cooperative clients have accumulated an impact factor exceeding 900. Jingneng Biotechnology has achieved a competitive advantage in the domestic second-generation sequencing and gene chip markets. Jingneng Biotechnology adheres to principles of customer first, shared happiness, mutual growth, and sustainable development, always maintaining a grateful mindset, striving to be an enterprise that satisfies society, customers, employees, and shareholders, and to become a leading company in providing health and medical products and technology services.